WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology
company that develops novel anticancer therapeutics using its
antibody-drug conjugate (ADC) technology, today announced that the
following presentation by Company management at an upcoming investor
conference will be webcast:
-
Cowen and Company 35th Annual Health Care
Conference
2:10 pm ET, March 2 in Boston, MA
The webcast will be accessible live through the "Investors" section of
the Company's website, www.immunogen.com;
a replay will be available at the same location for approximately a week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen
cell-killing agent specifically to cancer cells; the Company has also
developed antibodies with anticancer activity of their own. The first
product with ImmunoGen's ADC technology is Roche's Kadcyla®.
ImmunoGen has three wholly owned product candidates in clinical testing
with additional compounds in clinical testing through the Company's
partnerships with Amgen, Bayer HealthCare, Biotest, Novartis and Sanofi.
More information about ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of
the Roche Group.
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com
or
For
Media:
Pure Communications, Inc.
Dan Budwick, 973-271-6085
Source: ImmunoGen, Inc.
News Provided by Acquire Media